Alpine Immune Sciences (ALPN) Announces Earnings Results, Misses Expectations By $0.31 EPS
Alpine Immune Sciences (NASDAQ:ALPN) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.88) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.31), Zacks reports. Alpine Immune Sciences had a negative return on equity of 26.00% and a negative net margin of 1,602.19%.
ALPN stock opened at $4.80 on Friday. Alpine Immune Sciences has a one year low of $4.61 and a one year high of $11.75. The firm has a market capitalization of $66.77 million, a PE ratio of -4.00 and a beta of 0.94. The company has a quick ratio of 20.99, a current ratio of 20.99 and a debt-to-equity ratio of 0.05.
A number of analysts recently weighed in on the stock. ValuEngine upgraded shares of Alpine Immune Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday, October 23rd. Piper Jaffray Companies assumed coverage on shares of Alpine Immune Sciences in a research note on Thursday, September 27th. They set an “overweight” rating and a $12.00 price target for the company. Zacks Investment Research upgraded shares of Alpine Immune Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday, July 25th. Finally, Raymond James assumed coverage on shares of Alpine Immune Sciences in a research note on Monday, August 13th. They set a “buy” rating and a $13.00 price target for the company. Two investment analysts have rated the stock with a sell rating and five have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $12.67.
ILLEGAL ACTIVITY WARNING: “Alpine Immune Sciences (ALPN) Announces Earnings Results, Misses Expectations By $0.31 EPS” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.dailypolitical.com/2018/11/10/alpine-immune-sciences-alpn-announces-earnings-results-misses-expectations-by-0-31-eps.html.
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.
Featured Article: Buyback For Investors Defined
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.